Editas Medicine (EDIT) Appoints Lisa A. Michaels, M.D., as Chief Medical Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company’s Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michaels will lead clinical research and drug development for the Company’s pipeline of experimental medicines.

“We are thrilled to have Lisa join our team, bringing her ability to translate concepts from ‘bench to bedside’, with proven results in design and execution of multinational clinical trials,” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine. “Her corporate and academic drug development expertise will be instrumental in advancing our mission to develop and deliver transformative medicines to people living with serious diseases.”

Lisa Michaels, M.D., Executive Vice President and Chief Medical Officer, Editas Medicine, commented, “Editas Medicine is a leader in the development of the next generation of medicines to treat diseases with few approved medicines. I am excited to join the team as we just reacquired the rights to our ocular pipeline and are on the cusp of bringing EDIT-301, our potentially best-in-class medicine for the treatment of sickle cell disease, to the clinic. I look forward to working with the team to advance the development of EDIT-101, EDIT-301, and EDIT-201 in the near term as well as additional medicines in the future to treat serious diseases with unmet medical needs.”

Dr. Michaels has more than 25 years of experience in clinical research and drug development in both industry and academia. Dr. Michaels joins Editas Medicine from Bayer Pharmaceuticals where she spent more than 10 years in drug development, leading teams from early research and drug discovery through regulatory approval, commercial launch, and life cycle management. Most recently, she served as head of Bayer’s Rare Diseases, Cell & Gene Therapy therapeutic area.

Earlier in her career, Dr. Michaels spent more than 15 years at the Robert Wood Johnson Medical School at Rutgers University in academic practice, working in areas including benign and malignant hematology, solid tumors, bone marrow failure syndromes, thrombosis and hemostasis, and immunologic disorders including cytopenias and immune deficiencies.

Dr. Michaels received her M.D. at the University of Virginia, Charlottesville during which she received additional training in translational research in autoimmune disease, immune deficiencies, and disorders of complement, at the National Institute for Allergy and Infectious Disease in Washington, DC, and completed a preceptorship in pediatric cardiovascular care at Mayo Clinic, in Rochester, Minnesota. Dr. Michaels completed her residency and qualification in pediatrics at Duke University and post-graduate fellowship and qualification in hematology and oncology at the Children’s Hospital of Philadelphia.

You May Also Be Interested In

• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• Western Digital (WDC) posts FQ3 earnings, revenue beat; shares down
• Rollins (ROL) Appoints Louise S. Sams to its Board